The blood-retina barrier tight junctions and barrier modulation

Advances in Experimental Medicine and Biology

Volumn 763, Issue , 2013, Pages 70-84

  Campbell, Matthew ^a   Humphries, Peter ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CLAUDIN; CLAUDIN 5; COMPLEMENTARY DNA; DOXYCYCLINE; OCCLUDIN; PARVOVIRUS VECTOR; PROTEIN ZO1; PROTEIN ZO2; PROTEIN ZO3; RANIBIZUMAB; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SUNITINIB; TANESPIMYCIN; TIGHT JUNCTION PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ARTICLE; BLOOD BRAIN BARRIER; BLOOD RETINA BARRIER; CELL DENSITY; CELL PROLIFERATION; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LEBER CONGENITAL AMAUROSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RETINA MACULA AGE RELATED DEGENERATION; RETINOPATHY; SUBRETINAL NEOVASCULARIZATION; TIGHT JUNCTION; TREATMENT DURATION; VIRAL GENE DELIVERY SYSTEM;

EID: 84934443699     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4711-5_3     Document Type: Article

References (78)

1. Forrester JV, Dick AD, McMenamin PG, eds. The Eye. Philadelphia: Elsevier Health Sciences, 2001
2. Antonetti DA, Lieth E, Barber AJ, Gardner TW. Molecular mechanisms ofvascularpenneability in diabetic retinopathy. Semin Ophthalmol1999; 14:240-8
3. Marmorstein AD, Finnemann SC, Bonilha VL, Rodriguez-Boulan E. Morphogenesis of the retinal pigment epithelium: Toward understanding retinal degenerative diseases. Ann N Y Acad Sci 1998; 857: 1-12
4. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Patho12005; 167: 1451-9
5. Bazzoni G, Martinez-Estrada OM, Orsenigo F, et al. Interaction of junctional adhesion molecule with the tight junction components ZO-I, cingulin, and occludin. J Bioi Chern 2000; 275:20520-6
6. Bazzoni G, Martinez-Estrada OM, Mueller F, et al. Homophilic interaction of junctional adhesion molecule. J Bioi Chern 2000; 275:30970-6
7. Bazzoni G. The JAM family of junctional adhesion molecules. Curr Opin Cell Bioi 2003; 15:525-30
8. Bazzoni G, Dejana E. Endothelial cell-To-cell junctions: Molecular organization and role in vascular homeostasis. Physiol Rev 2004; 84:869-901
9. Farquhar MG, Palade GE. Junctional complexes in various epithelia. J Cell Bioi 1963; 17:375-412
10. Sakakibara A, Furuse M, Saitou M, et al. Possible involvement of phosphorylation of occludin in tight junction fonnation. J Cell Bioi 1997; 137:1393-401
11. Fanning AS, Anderson JM. PDZ domains and the formation of protein networks at the plasma membrane. Curr Top Microbiollmmunol1998; 228:209-33
12. Riesen FK, Rothen-Rutishauser B, Wunderli-Allenspach H. AZOI-GFP fusion protein to study the dynamics of tight junctions in living cells. Histochem Cell Bioi 2002; 117:307-15
13. Zahraoui A, Louvard D, Galli T. Tight junction, a platfonn for trafficking and signaling protein complexes. J Cell Bioi 2000; 151:F31-6
14. Zahraoui A. [Tight junctions, a platform regulating cell proliferation and polarity]. Med Sci (Paris) 2004; 20:580-5
15. Balda MS, Matter K. The tight junction protein ZO-I and an interacting transcription factor regulate ErbB-2 expression. EMBO J 2000; 19:2024-33
16. Balda MS, Garrett MD, Matter K. The ZO-I-Associated Y-box factor ZONAB regulates epithelial cell proliferation and cell density. J Cell Bio12003; 160:423-32
17. Vinores SA, Campochiaro PA, Lee A, et al. Localization of blood-retinal barrier breakdown in human pathologic specimens by immunohistochemical staining for albumin. Lab Invest 1990; 62:742-50
18. Vinores SA, Kuchle M, Derevjanik NL, et al. Blood-retinal barrier breakdown in retinitis pigmentosa: Light and electron microscopic immunolocalization. Histol Histopathol1995; 10:913-23
19. Dorchy H. Characterization of early stages of diabetic retinopathy. Importance of the breakdown of the blood-retinal barrier. Diabetes Care 1993; 16:1212-4
20. Dorchy H, ToussaintD. Fluorescein leakage: First sign of juvenile diabetic retinopathy. Lancet 1978; I: 1200
21. Carney MD, Paylor RR, Cunha-Vaz JG, et al. Iatrogenic choroidal neovascularization in sickle cell retinopathy. Ophthalmology 1986; 93: 1163-8
22. Mitic LL, Schneeberger EE, Fanning AS, Anderson JM. Connexin-oceludin chimeras containing the ZO-binding domain of occludin localize at MDCK tight junctions and NRK cell contacts. J Cell Bioi 1999; 146:683-93
23. Furuse M, Hirase T, Itoh M, et al. Occludin: A novel integral membrane protein localizing at tight junctions. J Cell BioI 1993; 123:1777-88
24. Furuse M, Itoh M, Hirase T, et al. Direct association of occludin with ZO-I and its possible involvement in the localization of occludin at tight junctions. J Cell BioI 1994; 127: 1617-26
25. Gonzalez-Mariscal L, Betanzos A, Avila-Flores A. MAGUK proteins: Structure and role in the tight junction. Semin Cell Dev BioI 2000; 11 :315-24
26. Gonzalez-Mariscal L, Namorado MC, Martin D, et al. Tight junction proteins ZO-I, ZO-2, and occludin along isolated renal tubules. Kidney Int 2000; 57:2386-402
27. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Bioi 2003; 81:1-44
28. Feldman GJ, Mullin JM, Ryan MP. Occludin: Structure, function and regulation. Adv Drug Deliv Rev 2005; 57:883
29. McCarthy KM, Skare IB, Stankewich MC, et al. Occludin is a functional component of the tight junction. J Cell Sci 1996; 109:2287-98
30. Brankin B, Campbell M, Canning P, et al. Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium. Exp Eye Res 2005; 81:22-31
31. Campbell M, Collery R, McEvoy A, et al. Involvement of MAPKs in endostatin-mediated regulation of blood-retinal barrier function. Curr Eye Res 2006; 31: 1033-45
32. Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation oftight j unction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Bioi Chern 1999; 274:23463-7
33. Wong V. Phosphorylation of occludin correlates with oceludin localization and function at the tight junction. Am J Physiol 1997; 273:CI859-67
34. Staddon JM, Smales C, Schulze C, et al. p120, a pl20-related protein (pI00), and the cadherin/catenin complex. J Cell Bioi 1995; 130:369-81
35. Kale G, Naren AP, Sheth P, Rao RK. Tyrosine phosphorylation of occludin attenuates its interactions with ZO-I, ZO-2, and ZO-3. Biochem Biophys Res Commun 2003; 302:324-9
36. Rao RK, Baker RD, Baker SS, et al. Oxidant-induced disruption of intestinal epithelial barrier function: Role of protein tyrosine phosphorylation. Am J Physiol 1997; 273 :G812-23
37. Saitou M, Fujimoto K, Doi Y, et al. Oceludin-dcficient embryonic stem cells can differentiate into polarized epithelial cells bearing tight junctions. J Cell Bioi 1998; 141 :397-408
38. Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA. Identification of ZO-I: A high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Bioi 1986; 103:755-66
39. Woods DF, Bryant PJ. ZO-I, DlgA and PSD-95/SAP90: Homologous proteins in tight, septate and synaptic cell junctions. Mech Dev 1993; 44:85-9
40. Weng Z, Rickles RJ, Feng S, et al. Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions. Mol Cell BioI 1995; 15:5627-34
41. Balda MS, Anderson JM. Two classes of tight junctions are revealed by ZO-I isoforms. Am J Physiol 1993; 264:C918-24
42. Gottardi CJ, Arpin M, Fanning AS, Louvard D. The junction-Associated protein, zonula occludens-I, localizes to the nucleus before the maturation and during the remodeling of cell-cell contacts. Proc Natl Acad Sci USA 1996; 93: 10779-84
43. Itoh M, Nagafuchi A, Moroi S, Tsukita S. Involvement of ZO-I in cadherin-based cell adhesion through its direct binding to alpha catenin and actin filaments. J Cell BioI 1997; 138: 181-92
44. Itoh M, Nagafuchi A, Yonemura S, et al. The 220-kD protein colocalizing with cadherins in non-epithelial cells is identical to ZO-l, a tight junction-Associated protein in epithelial cells: CDNA cloning and immunoelectron microscopy. J Cell Bioi 1993; 121 :491-502
45. ltohM, MoritaK, Tsukita S. Characterization ofZO-2 as aMAG UK family member associated with tight as well as adherens junctions with a binding affinity to oceludin and alpha catenin. J BioI Chern 1999; 274:5981-6
46. Giepmans BN, Moolenaar WH The gap junction protein connexin43 interacts with the second PDZ domain of the zona oceludens-I protein. CurrBio11998; 8:931-4
47. Balda MS, Garrett MD, Matter K. The ZO-l-Associated V-box factor ZONAB regulates epithelial cell proliferation and cell density. J Cell BioI 2003; 160:423-32
48. Kausalya P J, Reichert M, Hunziker W. Connexin45 directly binds to ZO-l and localizes to the tight junction region in epithelial MDCK cells. FEBS Lett 2001; 505:92-6
49. Hoover KB, Liao SY, Bryant PJ. Loss of the tight junction MAG UK ZO-l in breast cancer: Relationship to glandular differentiation and loss of heterozygosity. Am J Pathol 1998; 153: 1767-73
50. Tserentsoodol N, Shin BC, Suzuki T, Takata K. Colocalization of tight junction proteins, occ1udin and ZO-I, and glucose transporter GLUT I in cells of the blood-ocular barrier in the mouse eye. Histochem Cell BioI 1998; 110:543-51
51. Campbell M, Humphries M, Kennan A, et al. Aberrant retinal tight junction and adherens junction protein expression in an animal model of autosomal recessive Retinitis pigmentosa: The Rho(-I-) mouse. Exp Eye Res 2006; 83:484-92
52. Campbell M, Humphries M, Kenna P, et al. Altered expression and interaction of adherens junction proteins in the developing OLM of the Rho(-I-) mouse. Exp Eye Res 2007; 85:714-20
53. Freddo TF. Intercellular junctions ofthe iris epithelia in Macaca mulatta.Invest Ophthalmol Vis Sci 1984; 25: I 094-1 04
54. Wittchen ES, Haskins J, StevensonBR. Protein interactions at the tight junction. Actin has multiple binding partners, and ZO-I forms independent complexes with ZO-2 and ZO-3. J BioI Chern 1999; 274:35179-85
55. D'Atri F, Nadalutti F, Citi S. Evidence for a functional interaction between cingulin and ZO-l in cultured cells. J BioI Chern 2002; 277:27757-64
56. Betanzos A, Huerta M, Lopez-Bayghen E, et al. The tight junction protein ZO-2 associates with Jun, Fos and C/EBP transcription factors in epithelial cells. Exp Cell Res 2004; 292:51-66
57. Jaramillo BE, Ponce A, Moreno J, et al. Characterization of the tight j unction protein ZO-2 localized at the nucleus of epithelial cells. Exp Cell Res 2004; 297:247-58
58. Haskins J, Gu L, Wittchen ES, et al. ZO-3, a novel member of the MAG UK protein family found at the tight junction, interacts with ZO-I and occludin. J Cell BioI 1998; 141:199-208
59. Inoko A, ltoh M, Tamura A, et al. Expression and distribution of ZO-3, a tight junction MAGUK protein, in mouse tissues. Genes Cells 2003; 8:837-45
60. Islas S, Vega J, Ponce L, Gonzalez-Mariscal L. Nuclear localization of the tight junction protein ZO-2 in epithelial cells. Exp Cell Res 2002; 274: 138-48
61. Furuse M, Fujita K, Hiiragi T, et al. Claudin-l and-2: Novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Bioi 1998; 141: 1539-50
62. Furuse M, Sasaki H, Fujimoto K, Tsukita S. A single gene product, c1audin-l or-2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J Cell Bioi 1998; 143:391-401
63. Inai T, Kobayashi J, Shibata Y. Claudin-l contributes to the epithelial barrier function in MDCK cells. Eur J Cell BioI 1999; 78:849-55
64. Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell BioI 2003; 161 :653-60
65. Masland RH. The fundamental plan of the retina. Nat Neurosci 2001; 4:877-86
66. Swaroop A, Chew EY, Rickman CB, et al. Unraveling a multifactorial late-onset disease: From genetic susceptibility to diseasemechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet 2009, 10: 19.43
67. ResnikoffS, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82:844-51
68. CATT Research Group. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908
69. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: A literature review (2007) Retina. Sep;27(7):816-24
70. Pardridge WM. Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol 2006; 6:494-500
71. Piontek J, Winkler L, W olburg H, et al. Formation oftight junction: Determinants ofhomophilic interaction between classic claudins. FASEB J 2008; 22:146-58
72. Campbell M, Kiang AS, Kenna PF, et al. RNAi-mediated reversible opening of the blood-brain barrier. 2008. J Gene Med. Aug; 10(8):930-47
73. Campbell M, Nguyen ATH, Kiang AS, et al. An experimental platform for systemic drug delivery to the retina. Proe Natl Aead Sci USA 2009; 106:17817-22
74. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358:2240-8
75. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358:2231-9
76. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-Associated virus gene vector: Short-Term results of a phase I trial. Hum Gene Ther 2008; 19:979-90
77. Foust KD, Nurre E, Montgomery CL, et al. Intravascular AA V9 preferentially targets neonatal neurons and adult astroeytes. Nat Bioteehnol 2009; 27:59-65
78. Campbell M, Humphries MM, Nguyen ATH, et al. Systemic low molecular weight drug delivery to pre-selected neuronal regions. EMBO Mol Med 20 II; 3:235-45